

05.03.2018

08:30 - 09:15 Opening and welcome + Keynote Room Scene AB

Moderation: G. Giaccone¹, J. Tabernero²; ¹Washington Dc, MD/US, ²Barcelona, ES

08:30 - 08:40 ESMO Welcome address
J. Tabernero, Barcelona, ES

08:40 - 08:48 TAT 2018 Scientific Welcome address
G. Giaccone, Washington Dc, MD/US

08:48 - 08:50 Presentation of the TAT 2018 Honorary Award
G. Giaccone, Washington Dc, MD/US

08:50 - 09:15 TAT 2018 Honorary Award Keynote Address
J. Soria, Villejuif, CEDEX/FR

09:15 - 10:45 Novel immuno targets Room Scene AB

Moderation: I. Melero¹, G. Trinchieri²; ¹Pamplona, ES, ²Bethesda, US

09:15 - 09:30 1IN - TREX1 as a gate-keeper of cGAS/STING-mediated activation of interferon type I in cancer cells treated with DNA-damaging agents
S. Demaria, New York, NY/US

09:30 - 09:45 2IN - Targeting IDO1 function in tumor immunotherapy
F. Fallarino, Perugia, IT

09:45 - 10:00 3IN - Arginase inhibitors
V. Bronte, Verona, IT

10:00 - 10:15 4IN - CD137
I. Melero, Pamplona, ES

10:15 - 10:30 5IN - TIGIT immunotherapy
H.M. Zarour, Pittsburgh, US

10:30 - 10:45 Q&A

11:05 - 12:45	Novel epigenetic targets Moderation: S. Bates, New York, US	Room Scene AB
11:05 - 11:15	Introduction <u>S. Bates</u> , New York, US	
11:15 - 11:35	6IN - Synthetic lethality - EZH2 inhibitor tazemetostat in INI1-negative tumors <u>A. Italiano</u> , Bordeaux, CEDEX/FR	
11:35 - 11:55	7IN - Targeting histone H3K36me3-deficient cancers <u>T. Humphrey</u> , Oxford, GB	
11:55 - 12:15	8IN - BET domain inhibitors <u>I. Brana Garcia</u> , Barcelona, ES	
12:15 - 12:35	9IN - HDAC inhibitors and check point inhibitors <u>R. Bartz</u> , Planegg, DE	
12:35 - 12:45	Q&A / Panel Discussion	

13:30 - 15:00	Proffered Paper Session 1 Moderation: G. Shapiro ¹ , G. Schwartz ² ; ¹ Boston, US, ² New York, US	Room Scene AB
13:30 - 13:45	470 - Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer <u>M. Pegram</u> ¹ , E. Hamilton ² , A. Tan ³ , A. Storniolo ⁴ , N. Elgeiوشي ⁵ , S. Marshall ⁵ , S. Abdullah ⁵ , M. Patel ⁶ ; ¹ Stanford, CA/US, ² Nashville, TN/US, ³ Charlotte, TN/US, ⁴ Indianapolis, IN/US, ⁵ Gaithersburg, MD/US, ⁶ Sarasota, FL/US	
13:45 - 13:48	Q&A	
13:48 - 14:03	480 - CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL) <u>J. Michot</u> ¹ , R. Bouabdallah ² , J. Doorduijn ³ , U. Vitolo ⁴ , M.J. Kersten ⁵ , A. Chiappella ⁴ , P. Zinzani ⁶ , M. Pourdehnad ⁷ , Z. Nikolova ⁸ , V. Ribrag ¹ ; ¹ Villejuif, FR, ² Marseille, FR, ³ Rotterdam, NL, ⁴ Torino, IT, ⁵ Amsterdam, NL, ⁶ Bologna, IT, ⁷ San Francisco, CA/US, ⁸ Sevilla, ES	
14:03 - 14:06	Q&A	
14:06 - 14:21	490 - Downregulation of USP28 confers poorer overall survival to melanoma patients and causes resistance to RAF inhibitors <u>A. Saei</u> ¹ , M. Palafox ² , T. Benoukraf ¹ , N. Kumari ¹ , P. Iyengar ¹ , Z.F. Bin Adam Isa ¹ , H. Yang ¹ , W.L. Tam ¹ , V. Serra ² , P. Eichhorn ¹ ; ¹ Singapore, SG, ² Barcelona, ES	
14:21 - 14:24	Q&A	
14:24 - 14:39	500 - A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours <u>R. Plummer</u> ¹ , S. Halford ² , P. Jones ² , S. Wedge ³ , S. Hirschberg ² , G. Veal ¹ , G. Payne ² , M. Chenard-Poirier ² , H. Keun ² , U. Banerji ⁴ ; ¹ Newcastleupon Tyne, GB, ² London, GB, ³ Newcastle Upon Tyne, GB, ⁴ Sutton, Surrey/GB	
14:39 - 14:42	Q&A	
14:42 - 15:00	Panel discussion	

15:20 - 16:50	New concepts and new targets in haematology early drug development Moderation: V. Ribrag ¹ , A. Younes ² ; ¹ Villejuif, FR, ² New York, NY/US	Room Scene AB
15:20 - 15:50	10IN - Introduction and Metabolism interference or epigenetics treatment with special focus on haematological diseases <u>T. Mak</u> , Toronto, Ontario/CA	
15:50 - 16:05	11IN - Genomic-guided trials in lymphoma <u>A. Younes</u> , New York, NY/US	
16:05 - 16:20	12IN - Genomic-guided metabolism drug development in myeloid diseases <u>D. Schenkein</u> , Cambridge, US	
16:20 - 16:35	13IN - Personalized therapy in adult acute lymphocytic leukemia: Path to the cure <u>E. Jabbour</u> , Houston, US	
16:35 - 16:50	Q&A / Panel Discussion	
16:50 - 17:10	Selected poster presentations Moderation: G. Giaccone ¹ , J. Tabernero ² ; ¹ Washington Dc, MD/US, ² Barcelona, ES	Room Scene AB
16:50 - 16:55	Introduction	
16:55 - 17:00	51P - Active immunotherapy with a VEGF targeted vaccine HeberSaVax: The road so far and the future ahead <u>M. Bequet-Romero</u> ¹ , Y. Díaz ² , J. Ramírez ² , K. Selman-Housein ³ , F. Hernández-Bernal ² , A. De la Torre Santos ⁴ , J. Piñero ⁴ , C. Bermúdez ² , J. Gavidondo Cowley ² , M. Ayala Avila ² ; ¹ Cubanacán, Playa, Havana/CU, ² Cubanacán, Playa, CU, ³ Havana, CU, ⁴ Santa Clara, CU	
17:00 - 17:05	52P - A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors <u>J. Medina</u> ¹ , M. Hinterberger ² , M. Testori ¹ , M. Geiger ¹ , R. Giessel ¹ , P. Chaplin ¹ , H. Hochrein ¹ , H. Lauterbach ¹ ; ¹ Martinsried, DE, ² München, DE	
17:05 - 17:10	53P - Impact of chronic hepatitis virus infection on the feasibility and efficacy for Asian patients with hepatocellular carcinoma in phase I clinical trials <u>T. Koyama</u> ¹ , S. Kondo ¹ , T. Shimizu ¹ , Y. Fujiwara ¹ , S. Kitano ¹ , T. Ebata ² , A. Shimomura ¹ , C. Morizane ¹ , T. Okusaka ¹ , N. Yamamoto ¹ ; ¹ Tokyo, JP, ² Chiba, Chiba/JP	
17:10 - 18:00	Poster display	Foyer La Scene

- 17:10 - 17:10 54P - Identifying the oncogenic role of USP10 as the regulator of PTEN function in breast cancer
N. Kumari¹, A. Saei¹, C. Lalith¹, V. Serra², S. Jha¹, P. Eichhorn¹; ¹Singapore, SG, ²Barcelona, ES
- 17:10 - 17:10 55P - Protein expression and clinical significance of the NEDDylation pathway in myelodysplastic syndrome
F. Majidi¹, J. Strapatsas¹, S. Brille¹, I. Fey¹, F. Neumann², A. Berger², U. Germing¹, R. Haas¹, N. Gattermann¹; ¹Düsseldorf, DE, ²Cambridge, US
- 17:10 - 17:10 56P - Clinicopathological, predictive and prognostic significance of XRCC1-Ligase III heterodimer expression in ovarian cancer
M. Alabdullah, P. Moseley, S. Chan, E. Rakha, S. Madhusudan; Nottingham, GB
- 17:10 - 17:10 57P - NOX66 plus low dose carboplatin: A phase 1 safety and signalling study
G. Kelly¹, M. Messina¹, I. Minns²; ¹Sydney, NSW/AU, ²Sydney, AU
- 17:10 - 17:10 58P - Pharmacokinetics of ZR2002, a combi-molecule with EGFR and DNA-damaging properties and its efficacy in an orthotopic glioblastoma mouse model
Z. Sharifi¹, B. Meehan², P. Daniel², K. Eppert², B. Jean-Claude², J. Rak¹, B. Abdulkarim², S. Sabri²; ¹Montreal, QC/CA, ²Montreal, CA
- 17:10 - 17:10 59P - Synergistic effects of PARP inhibitors and ionizing radiation on growth and survival of rhabdomyosarcoma cells
F. Megiorni¹, S. Camero², S. Ceccarelli², F. De Felice², F. Marampon³, B. Pizer⁴, R. Shukla⁴, V. Tombolini², C. Marchese², C. Dominici²; ¹Rome, IT, ²Roma, IT, ³L'aquila, IT, ⁴Liverpool, GB
- 17:10 - 17:10 60P - Investigating the role of nuclear sphingosine kinase 1 (SphK1) in lung cancer
F. Napolitano, R. Rosa, V. D'Amato, R. Orsini, P. Ciciola, C. Di Mauro, A. Santaniello, R. Marciano, S. De Placido, R. Bianco; Napoli, IT
- 17:10 - 17:10 61P - Preclinical evaluation of BET-bromodomain inhibitor TEN-010 as monotherapy and combination therapy in MYC-driven neuroblastoma
K. Firlle, A. Szymansky, M. Witthauer, H. Dorado-Garcia, J. Toedling, K. Schoenbeck, A. Henssen, F. Hertwig, A. Eggert, J. Schulte; Berlin, DE
- 17:10 - 17:10 62P - Targeting Wnt pathway reduces primary tumor and metastasis in breast cancer models
S. Goswami, New York, US
- 17:10 - 17:10 63P - EXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors
O. Le Saux¹, A. Italiano², D. Spaeth³, P. Heudel⁴, T. Filleron⁵, V. Pezzella⁶, M. Jimenez⁶, F. LEGRAND⁶, C. Ferté⁷; ¹Lyon, FR, ²Bordeaux, CEDEX/FR, ³Nancy, FR, ⁴Lyon, Cedex 08/FR, ⁵Toulouse, CEDEX 3/FR, ⁶Paris, FR, ⁷Villejuif, FR
- 17:10 - 17:10 64P - miRNA 200c sensitize pancreatic cancer stem cells to carbon ion beam irradiation
S. Sai¹, M. Suzuki¹, E.H. Kim²; ¹Chiba, JP, ²Seoul, KR

- 17:10 - 17:10 65P - Epigenetic regulation of tumor metabolism
S. Shivanna¹, J. Liu², J. Pawling², J. Dennis², E. Zacksenhaus²; ¹Toronto, CA, ²Toronto, ON/CA
- 17:10 - 17:10 66P - Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor targeting the NOTCH transcription complex
D. Weber¹, R. Lehal¹, V. Frismantas², J. Bourquin², M. Bauer¹, M. Murone¹, F. Radtke³; ¹Basel, CH, ²Zürich, CH, ³Lausanne, CH
- 17:10 - 17:10 67P - DNA promoter methylation status and protein expression of SHh and IHh in serous ovarian carcinomas
V. Karin¹, A. Skrtic¹, F. Skenderi², N. Ibisevic², S. Vranic³, L. Serman¹; ¹Zagreb, HR, ²Sarajevo, BA, ³Doha, QA
- 17:10 - 17:10 68P - MicroRNA-21 functions as a prognosis predictor in head of pancreas tumor
F. Aksoy, S. Aksoy, B. Tunca, H.Z. Dundar, P. Sarkut, Y. Ozen, U. Egeli, G. Cecener, O. Yerci, E. Kaya; Bursa, TR
- 17:10 - 17:10 69P - RAB25 a potential therapeutic target in luminal B breast cancer molecular subtype
L. Addou-Klouche, Marseille, FR
- 17:10 - 17:10 70P - mTORC1 and its downstream effectors predict poor outcome in primary epithelial ovarian cancer
M. Alabdullah¹, I. Miligy², P. Moseley², S. Madhusudan², S. Chan², E. Rakha²; ¹Birmingham, GB, ²Nottingham, GB
- 17:10 - 17:10 71P - The effect of hTERT repression on the TERRA expression and telomere length in gastric cancer
H. Akhavan¹, S. Vahidi¹, S. Sorayyayi¹, S.S. Hosseini-Asl²; ¹Rasht, IR, ²Ardabil, IR
- 17:10 - 17:10 72P - Up-regulation of miR-1266-5p suppressed hTERT expression and telomerase activity in cancer cell lines
S.S. Hosseini-Asl¹, S. Sorayyayi², S. Vahidi²; ¹Ardabil, IR, ²Rasht, IR
- 17:10 - 17:10 73P - Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer
C. Rodriguez-Aguayo¹, E. Bayraktar², C. Ivan², E. Fuentes-Mattei², B. Ozpolat², R. Mitra², A. Sood², G. Calin², G. Lopez-Berestein²; ¹Houston, US, ²Houston, TX/US
- 17:10 - 17:10 74P - Promoter hypermethylation of Wnt pathway inhibitor SFRP1 gene and its expression levels in human astrocytomas
A. Kafka, V. Karin, L. Serman, A. Bukovac, N. Njirić, A. Jakovcevic, N. Pecina-Slaus; Zagreb, HR
- 17:10 - 17:10 75P - Role of p21-activated kinase (PAK) in K-RAS mutant human colorectal cancer models
R. Orsini, V. D'Amato, R. Rosa, C. Di Mauro, P. Ciciola, A. Servetto, F. Napolitano, R. Marciano, S. De Placido, R. Bianco; Napoli, IT
- 17:10 - 17:10 76P - Re-sensitising endocrine resistant ER+ breast cancer by targeting epigenetic modifying enzymes

G. Borchert, F. Casciello, G. Kelly, E. Baxter, F. Gannon, J. Lee; Brisbane, AU

- 17:10 - 17:10 77P - Leptin receptor gene (AVG) polymorphism (rs1137101) and renal cell carcinoma
A. Alhanafy, A. Zahran, A. Abdalla, S. Elhefnawy, H. Kasem; Shebin El Kom, EG
- 17:10 - 17:10 78P - Post-transcriptional regulation of Cyclooxygenase-2 (COX-2) by Sodium Butyrate (NaBt) in the presence of chemically induced stress in colon epithelial cells.
S. Enayat, A. Torun, S. Banerjee; Ankara, TR
- 17:10 - 17:10 79P - Role of DNA methylation in early detection of gastric cancer in patient with chronic atrophied gastritis
F. Djuraev, Tashkent, UZ
- 17:10 - 17:10 80P - Development of novel modified aptamers to target Axl receptor in ovarian cancer
P. Amero¹, C. Rodriguez-Aguayo², G. Lokesh², E. Bayraktar², C. Ivan², R. Chaudhari², S. Zhang², D. Volk², A. Sood², G. Lopez-Berestein²; ¹Houston, US, ²Houston, TX/US
- 17:10 - 17:10 81P - Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer
J. Hermanowicz, A. Tankiewicz-Kwedlo, A. Surażyński, K. Pawlak, D. Pawlak; Bialystok, PL
- 17:10 - 17:10 82P - Introduction of a novel cancer cell targeted fusion protein: DT386-BR2
A. Jahanian-Najafabadi, F. Shafiee, M. Rabbani; Isfahan, IR
- 17:10 - 17:10 83P - Artemisia absinthium extract loaded polymeric nanoparticles as the therapeutic remedy for breast cancer
M. Mughees, M. Samim, S. Wajid; New Delhi, IN
- 17:10 - 17:10 84P - Dual inhibition of AXL and FN14 sensitizes cisplatin in resistant non-small cell lung carcinoma by inducing higher caspase 3 cleavage through FHIT upregulation, both in vivo and in vitro
S. Mukherjee¹, D. Suresh², A. Zambre¹, A. Upendran², R. Kannan²; ¹Columbia, US, ²Columbia, MO/US
- 17:10 - 17:10 85P - Repurposing chemotherapy drugs: The induction of immunogenic cell death in tumor cells as a tool leading to new formulations of cancer vaccines
A. Infante-Cruz¹, D. Bernal-Estévez², C. Parra-López²; ¹Bogotá, CO, ²Bogota, CO
- 17:10 - 17:10 86P - Pim1 promotes ovarian cancer growth and the Warburg effect via c-Myc-glycolysis signaling axis
Y. Wu¹, Y. Deng¹, Y. Duan¹, S. Wang², J. Li¹, J. Zhu¹, W. Weng¹, X. Wu¹; ¹Shanghai, CN, ²Kunming, CN
- 17:10 - 17:10 87P - Towards the identification of the mechanism of action of antitumor 1-methyl-D-tryptophan
M.T. Pallotta, A. Iacono, E. Albini, C. Orabona, M.L. Belladonna, R. Bianchi, A. Coletti, F. Greco, A. Macchiarulo, U. Grohmann; Perugia, IT
- 17:10 - 17:10 88P - Relationship between functions and intracellular localization of the immune checkpoint target indoleamine 2,3-dioxygenase 1

A. Iacono¹, A. Pompa¹, F. De Marchis¹, M. Bellucci¹, F. Grassi², U. Grohmann¹, M.T. Pallotta¹; ¹Perugia, IT, ²Bellinzona, CH

- 17:10 - 17:10 89P - A polyphenol-rich extract from olive-mill waste waters targets the IL-6/STAT3 pathway in prostate cancer cell lines
A. Albini, D. Baci, A. Bruno, D. Noonan; Milan, IT
- 17:10 - 17:10 90P - Cytotoxicity of methanol extracts of 10 Cameroonian medicinal plants towards multi-factorial drug-resistant cancer cell lines
M. Flora, Yaounde, CM
- 17:10 - 17:10 91P - Novel effect of acetyl-11-keto-boswellic acid (AKBA) on mitophagy-induced apoptosis using cellular proteomic profiling
F. Al Zadjali, Muscat, OM
- 17:10 - 17:10 92P - Targeting PI3K-AKT pathway in Gemcitabine Resistant Pancreatic Duct Adenocarcinoma
O. Ge¹, J. Gu², Y. Zhu², J. Zhang², R. Monk³, L. Schomburg³; ¹Nanjing, Jiangsu Province/CN, ²Shanghai, CN, ³Berlin, DE
- 17:10 - 17:10 93P - In silico identification and in vitro assessment of a potential anticancer peptide sequence retrieved from the Red sea metagenomics library
M. Imam¹, A. Amleh²; ¹New Cairo, EG, ²Cairo, EG
- 17:10 - 17:10 94P - New insights in the antitumor effects of β -caryophyllene in breast cancer cells: The role of cannabinoid and adrenergic systems
A. Di Sotto¹, D. Romaniello², G. Freddoni², L. Abete², R. Cocchiola², S. Di Giacomo², F. Altieri², G. Mazzanti², M. Eufemi²; ¹Rome, IT, ²Roma, IT
- 17:10 - 17:10 95P - Energy restriction as a novel approach targeting breast cancer stem cells multi-drug resistance
D. Zaher, H. Omar; Sharjah, AE
- 17:10 - 17:10 96P - Delivery of paclitaxel and everolimus in dual-targeted polymeric nanoparticles to breast cancer cells
L. Houdaihed¹, J. Evans², C. Allen²; ¹Toronto, CA, ²Toronto, ON/CA
- 17:10 - 17:10 97P - Vascular targeted photodynamic therapy for pancreatic ductal adenocarcinoma: A pre-clinical success
R. Goldschmidt¹, N. Koudinova², K. Sasson², D. Preise², L. Agemy², V. Mohan², F. Bochner², I. Sagi², M. Neeman², A. Scherz²; ¹Tel Aviv, IL, ²Rehovot, IL
- 17:10 - 17:10 98P - Effect of prolactin receptor antagonist in different cancer models
A. Al Kharusi¹, G. Norstedt²; ¹Muscat, OM, ²Stockholm, SE
- 17:10 - 17:10 99P - Effective model for antitumor drugs screening based on 3D growth system of MCF-7
T. Nikolaienko, L. Garmanchuk, Y. Stupak; Kiev, UA

- 17:10 - 17:10 100P - Antitumor effect of dendritic cells loaded with Fe₂O₃ magnetic nanocomplex in mice with sarcoma 37
M. Inomistova, N. Khranovska, O. Skachkova, O. Gorbach, I. Shumeiko, V. Orel; Kiev, UA
- 17:10 - 17:10 101P - Delivery of E-cadherin (CDH1) gene and epidermal growth factor receptor (EGFR) siRNA, using carbonate apatite as a promising vehicle in treatment of breast cancer
M. Ashaie¹, I. Othman¹, K.K. Tha¹, E. Chowdhury²; ¹Selangor, MY, ²Selangor Malaysia, MY
- 17:10 - 17:10 102P - Functional characterization of mammaglobin-1 isoform in breast cancer
R. Guerrette, G. Robichaud; Moncton, CA
- 17:10 - 17:10 103P - Afatinib is active in osteosarcoma in vitro models
M. Cruz Ramos¹, Y. Zamudio-Cuevas², K. Martínez-Flores², D. Medina-Luna², G. Martínez-Nava², J. Fernández-Torres², A. López Reyes², F. Solca³; ¹Madrid, ES, ²Mexico D.f., MX, ³Vienna, AT
- 17:10 - 17:10 104P - Augmentation of NAD⁺ levels by enzymatic action of NAD(P)H quinone oxidoreductase 1 attenuates adriamycin-induced cardiomyopathy
D. Khadka, G. Oh, H. Kim, S. Lee, A. Shen, S. Lee, A. Pandit, S. Sharma, S. Yang, H. So; Iksan, KR
- 17:10 - 17:10 105P - Targeted delivery of albumin-binding caspase-3 cleavable docetaxel prodrug to radiation exposed local tumor
Y. Cho, H. Kim, Y. Byun; Seoul, KR
- 17:10 - 17:10 106P - Antiproliferative effect of trastuzumab and nimotuzumab with EGF on breast cancer cells MCF-7
V. Nikulina, L. Garmanchuk, T. Nikolaienko; Kiev, UA
- 17:10 - 17:10 107P - Development of an in vitro tumour model to evaluate drug efficacy and epidermal mesenchymal transition in triple negative breast cancer.
T. Azimi, London, GB
- 17:10 - 17:10 108P - The role of citrus peel extract in inhibiting progression and recurrence of prostate cancer
B. Shammugasamy¹, P. Valtchev², F. Dehghani², Q. Dong²; ¹Sydney, AU, ²Sydney, NSW/AU
- 17:10 - 17:10 109P - Multiphysics modelling of alpha-immuno-conjugate delivery and background dose
T. Liu, Chalk River, Ontario, CA
- 17:10 - 17:10 110P - CellMiner and CellMiner cross-database (CDB): Resources for the exploration of pharmacogenomics using cancerous cell-lines
W. Reinhold, Y. Pommier; Bethesda, US
- 17:10 - 17:10 111P - Effect of IFN α -2b on migrational ability of tumor cells on early stages of breast cancer development
T. Herheliuk¹, O. Perepelytsina², L. Ostapchenko³, M. Sydorenko²; ¹Kiev, UA/UA, ²Kiev, UA, ³Kyiv, UA
- 17:10 - 17:10 112P - Combination effects of MEK inhibitors with statins on cancer cells
M. IIZUKA-Ohashi, M. Watanabe, T. Taguchi, T. Sakai; Kyoto, JP

- 17:10 - 17:10 113P - A new therapeutic approach in liposomal DDS equipped with radical pair system
H. Nakagawa, K. Nakamura, M. Ohuchi; Tokyo, JP
- 17:10 - 17:10 114P - Impact by age on dose-limiting toxicities in phase 1 oncology trials of cytotoxic agents and molecular targeted agents
T. Ebata¹, A. Shimomura², T. Koyama², S. Iwasa², S. Kondo², S. Kitano², K. Yonemori², Y. Fujiwara², T. Shimizu², N. Yamamoto²; ¹Chiba, Chiba/JP, ²Tokyo, JP
- 17:10 - 17:10 115P - Sequencing of cancer panels through “next generation sequencing” (NGS) in the clinical practice of a phase 1 trial unit
A.L. Wiermann¹, V. Boni², M.J. de Miguel², F. Lopéz-Ríos², E. Calvo²; ¹Curitiba, PR/BR, ²Madrid, ES
- 17:10 - 17:10 116P - A targeted genomic analysis uncovered a large spectrum of acquired resistance mechanisms to BRAF inhibitor therapy in metastatic melanoma patients
B. Louveau¹, C. Reger de Moura¹, M. Battistella¹, A. Sadoux¹, I. Chami¹, J. Caramel², S. Dalle³, N. Dumaz¹, C. Lebbe⁴, S. Mourah¹; ¹Paris, FR, ²Lyon, FR, ³Pierre Bénite, CEDEX/FR, ⁴Paris, CEDEX 10/FR
- 17:10 - 17:10 117P - External validation of the Gustave Roussy immune score (GRIm score) in an unselected cohort of patients treated at the Clinica Universidad de Navarra
L. Ceniceros¹, I. Gardeazabal¹, M. Rodriguez¹, J.L. Perez Gracia², I. Melero¹, M. Ponz-Sarvisé¹, E. Castanon Alvarez¹; ¹Pamplona, ES, ²Salamanca, ES
- 17:10 - 17:10 118P - Precision trial designer-web: A web-based app to assist in the design of genomics-driven trials
L. Mazzarella¹, G. Melloni², A. Guida¹, G. Curigliano¹, M. Kamal³, C. Le Tourneau³, P. Pelicci¹; ¹Milan, IT, ²Boston, US, ³Paris, FR
- 17:10 - 17:10 119P - Adjuvant radiation therapy effects systemic immune response cells in female breast cancer patients
N. Lewin, Jönköping, SE
- 17:10 - 17:10 120P - Comparison of model-based dose escalation design with rule-based design of phase I oncology trials
A. Shimomura, T. Ebata, T. Koyama, S. Iwasa, S. Kondo, S. Kitano, K. Yonemori, Y. Fujiwara, T. Shimizu, N. Yamamoto; Tokyo, JP
- 17:10 - 17:10 121P - Real-life tolerance and plasma exposure assessment of lenvatinib in thyroid metastatic cancer patients
L. Goldwirt¹, V. Madelain¹, C. Chougnat², T. Benichou¹, H. Sauvageon¹, S. Mourah¹; ¹Paris, FR, ²Paris, CEDEX 10/FR
- 17:10 - 17:10 122P - Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT
F. Cecchi, Rockville, MD/US
- 17:10 - 17:10 123P - Prediction of response to trasutuzumab/pertuzumab/taxane therapy by microRNA in HER2 positive advanced breast cancer

A. Kawachi, A. Shimomura, J. Matsuzaki, J. Kawauchi, S. Takizawa, H. Sakamoto, C. Shimizu, K. Tamura, T. Ochiya; Tokyo, JP

- 17:10 - 17:10 124P - Detection of KRAS mutation, MSI and TP53 status in Indonesian CRC patients with its association to PD-L1 expression
G. Kusumo¹, T. Putra¹, A. Budiayati¹, F. Rexana², A. Sudoyo², A. Kurniawan², A. Utomo¹, A. Utama¹; ¹East Jakarta, ID, ²Jakarta, ID
- 17:10 - 17:10 125P - Comparison of different testing methods for detection of BRAF V600 mutation in metastatic melanoma
J. Hernandez-Losa¹, Y. Ruano², I. Trigo Sanchez³, R. Somoza¹, B. Ferrer¹, F. Garcia Verdes-Montenegro², M. Urech², S. Ramon Y Cajal¹, J.J. Rios Martin³, J.L. Rodriguez-Peralto²; ¹Barcelona, ES, ²Madrid, ES, ³Sevilla, ES
- 17:10 - 17:10 126P - Assessment of genetic polymorphisms of CXCR5 on response to therapy of non-Hodgkin lymphoma (NHL)
T. Hashem¹, M. Elmasry², M. Makhoul²; ¹Giza, Menofya/EG, ²Cairo, EG
- 17:10 - 17:10 127P - Studies on the carcinogenic mechanisms of Growth Receptor Bound Protein 7 in breast cancer cells and its clinical therapeutic applications
L. Chen, Taipei, TW
- 17:10 - 17:10 128P - Erythromycin readthrough of APC nonsense stop codon mutation in Familial adenomatous polyposis
R. Kariv, N. Fliss-Isacov, M. Caspi, R. Arbesfeld; Tel Aviv, IL
- 17:10 - 17:10 129P - Identification of chromosomal aberrations using fluorescence in situ hybridization (fish) in bladder cancer patients of south Indian region
K. Kovendan¹, A. Meyyalazhagan², A. Jebanesan³, S. Vincent⁴; ¹Coimbatore, IN, ²Bergondo, ES, ³Chidambaram, IN, ⁴Chennai, IN
- 17:10 - 17:10 130P - To assess the pain control and tolerance to drug induced emesis in oral and neck carcinoma patients undergoing chemoradiation treated for pain relief with tapentadol (TAPAL -ER 50) vs. tramadol plus paracetamol with and without anti-emetic support
R. Narayanasamy, Chennai, IN
- 17:10 - 17:10 131P - Is HER2 positive disease a more aggressive breast cancer sub-type in young women?
R. Anghel¹, L. Gales², L. Serbanescu², B. Gusoiu², F. Topliceanu², O. Trifanescu¹; ¹Bucharest, Sec. 2/RO, ²Bucharest, RO
- 17:10 - 17:10 132P - MicroRNA dysregulation as a prognostic biomarker in wild-type RAS/RAF/PTEN/PI3 metastatic colon cancer treated with anti-EGFR therapeutics
S. Aksoy, O. Kanat, B. Tunca, H. Ertas, N. Ugras, E. Ozturk, T. Yilmazlar, G. Cecener, U. Egeli, O. Yerci; Bursa, TR
- 17:10 - 17:10 133P - The global forecast of prostate cancer drug-treatable populations eligible for targeted anticancer therapies (2017-2027)

N. Parihar, Bangalore, IN

- 17:10 - 17:10 134P - Impact of sorafenib on quality of life in hepatocellular carcinoma
A. Abraham¹, B. Nair¹, A. Anand¹, V. Kuriakose²; ¹Thiruvananthapuram (trivandrum), IN, ²Thiruvananthapuram (trivandrum), Kerala/IN
- 17:10 - 17:10 135P - Axitinib: An audit of dose adjustments, tolerability and efficacy in advanced renal cell carcinoma
R. Parkar, E. Boleti; London, GB
- 17:10 - 17:10 136P - Drug transporter pharmacogenetics as a predictor of chemotherapy-induced toxicity in lung cancer patients
Z. Zair, D. Singer; Coventry, GB
- 17:10 - 17:10 137P - Sunitinib 4:2 versus 2:1 regimen
R. Parkar, T. Lytra, E. Boleti; London, GB
- 17:10 - 17:10 138P - Preclinical testing of NEDD8 and proteasome inhibitors for a treatment-refractory, metastatic high-grade mucinous colorectal cancer patient
E. Torchio¹, C. Petti¹, C. Isella², G. Corti¹, M. Montone¹, B. Mussolin¹, A. Bardelli³, E. Medico²; ¹Candiolo, IT, ²Torino, IT, ³Candiolo, (TO)/IT
- 17:10 - 17:10 139P - Hepatocellular carcinoma (HCC) treated with sorafenib (SFB) and hepatitis C virus (HCV) infection
M. Rocha¹, A. Fortuna², A. Castro², A. Araújo²; ¹Vila Real, PT, ²Porto, PT
- 17:10 - 17:10 140P - The predictive role of estrogen receptor beta (ER-β) in androgen receptor (AR)-positive triple-negative breast cancer (TNBC)
A. Anestis, C. Mihailidou, S. Theocharis, D. Tryfonopoulos, A. Korogiannos, A. Koumariannou, E. Xingi, M. Kontos, A.G. Papavassiliou, M.V. Karamouzis; Athens, GR
- 17:10 - 17:10 141P - Self-questionnaire to assess patient's preferences for participation in phase I clinical trials
B. Verret¹, A. Perret¹, S. Delalogue¹, B. Besse², A. Le Cesne², A. Hollebecque¹, C. Baldini², C. Massard¹, J. Soria², S. Postel-Vinay¹; ¹Villejuif, FR, ²Villejuif, CEDEX/FR
- 17:10 - 17:10 142P - Targeted anticancer therapy and concomitant hypofractionated radiotherapy in breast cancer
E. Bonzano, M. Guenzi, R. Corvò; Genova, IT
- 17:10 - 17:10 143P - Aurora Kinase A (AURKA) is an independent predictor of recurrence in breast ductal carcinoma in situ (DCIS)
I. Miligy¹, A. Gaber², M. Toss¹, A. Hamad¹, C. Nolan¹, M. Diez-Rodriguez¹, I. Ellis¹, A. Green¹, E. Rakha¹; ¹Nottingham, GB, ²Shebin El Kom, EG
- 17:10 - 17:10 144P - The role of topoisomerase II-α (TOPO IIA) as a predictive factor for response to neoadjuvant anthracycline-based chemotherapy in locally advanced breast cancer
M. Gamea, Aswan, EG
- 17:10 - 17:10 145P - The clinical significance of lncRNA DANCR in upper rectal adenocarcinoma

F. Aksoy, S. Aksoy, B. Tunca, O. Işik, E. Ozturk, T. Yilmazlar, O. Yerci, U. Egeli, G. Cecener; Bursa, TR

17:10 - 17:10 146P - Activation of lung metastasis after lymph node dissection

A. Sukhbaatar, T. Takahashi, S. Mori, T. Kodama; Sendai, JP

17:10 - 17:10 147P - Clinicopathological significance of HER2 and EGFR expression in urothelial carcinoma: A single center study

G. Botiraliyeva, M. Tillyashaykhov, A. Yusupbekov; Tashkent, UZ

06.03.2018

09:00 - 10:30 Combining immune therapy and targeted therapies Room Scene AB

Moderation: M. Atkins¹, A. Marabelle²; ¹Washington Dc, US, ²Villejuif, FR

09:00 - 09:20 14IN - Combining CPI with anti-VEGF therapy

M. Atkins, Washington Dc, US

09:20 - 09:40 15IN - Combining immunotherapies with targeted therapies

S. Mariathasan, South San Francisco, CA/US

09:40 - 10:00 16IN - Combining PARP inhibitors with CPI

F. Lynce, Washington, US

10:00 - 10:20 17IN - MDICT report (consensus report)

L. Seymour¹, G. Giaccone², J. Tabernero³; ¹Kingston, Ontario/CA, ²Washington Dc, MD/US, ³Barcelona, ES

10:20 - 10:30 Q&A / Panel Discussion

11:00 - 12:30	Proffered Paper Session 2 Moderation: S. Bates ¹ , P. Wen ² ; ¹ New York, US, ² Boston, US	Room Scene AB
11:00 - 11:15	410 - A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma <u>K. Blum</u> ¹ , J. Abramson ² , M. Maris ³ , I. Flinn ⁴ , A. Goy ⁵ , J. Mertz ² , R. Sims ⁶ , F. Garner ⁶ , A. Senderowicz ² , A. Younes ⁷ ; ¹ Atlanta, US, ² Cambridge, MA/US, ³ Denver, CO/US, ⁴ Nashville, TN/US, ⁵ Hackensack, NJ/US, ⁶ Cambridge, US, ⁷ New York, NY/US	
11:15 - 11:18	Q&A	
11:18 - 11:33	420 - A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas <u>W. Harb</u> ¹ , J. Abramson ² , M. Lunning ³ , A. Goy ⁴ , K. Maddocks ⁵ , C. Lebedinsky ⁶ , A. Senderowicz ² , P. Trojer ² , W. Bradley ² , I. Flinn ⁷ ; ¹ Lafayette, IN/US, ² Cambridge, MA/US, ³ Omaha, NE/US, ⁴ Hackensack, NJ/US, ⁵ Columbus, OH/US, ⁶ Cambridge, US, ⁷ Nashville, TN/US	
11:33 - 11:36	Q&A	
11:36 - 11:51	430 - Unravelling the context specificity of signalling in KRAS mutant cancers: Implications for design of clinical trials <u>U. Banerji</u> ¹ , A. Stewart ² , E. Coker ² , A. Minchom ² , S. Pölsterl ² , A. Georgiou ² , B. Al-Lazikani ² ; ¹ Sutton, Surrey/GB, ² London, GB	
11:51 - 11:54	Q&A	
11:54 - 12:09	440 - CCTG IND.231: A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors <u>J. Hilton</u> ¹ , D. Cescon ² , P. Bedard ³ , H. Ritter ⁴ , D. Tu ⁴ , J. Soong ⁵ , K. Gelmon ⁶ , S. Aparicio ⁶ , L. Seymour ⁷ ; ¹ Ottawa, CA, ² Toronto, ON/CA, ³ Toronto, Ontario/CA, ⁴ Kingston, CA, ⁵ New Taipei City, TW, ⁶ Vancouver, British Columbia/CA, ⁷ Kingston, Ontario/CA	
12:09 - 12:12	Q&A	
12:12 - 12:30	Panel discussion	

13:45 - 15:15	Metabolic targets Moderation: P. Wen, Boston, US	Room Scene AB
13:45 - 14:05	18IN - Glioma and IDH targeting <u>D. Cahill</u> , Boston, US	
14:05 - 14:25	19IN - Tumor metabolism and drug targeting with a focus on in sarcoma and the tissue microenvironment (glutamate and arginine) <u>B. Van Tine</u> , St. Louis, Missouri/US	
14:25 - 14:45	20IN - T cell metabolism and metabolic reprogramming <u>J. Powell</u> , Baltimore, US	
14:45 - 15:05	21IN - Targeting of the LXR-cholesterol axis as a metabolic co-dependency for brain cancers <u>G. Villa</u> , Los Angeles, US	
15:05 - 15:15	Q&A	
15:45 - 17:15	DNA targets: Damage, repair and immunotherapy Moderation: R. Plummer, Newcastle Upon Tyne, Tyne and Wear/GB	Room Scene AB
15:45 - 16:05	22IN - Overview: Multiple ways to harness targeting DNA to treat cancer <u>R. Plummer</u> , Newcastle Upon Tyne, Tyne and Wear/GB	
16:05 - 16:25	23IN - Novel topoisomerase inhibitors <u>Y. Pommier</u> , Bethesda, US	
16:25 - 16:45	24IN - Targeting the DDR – DNA PK inhibition <u>F. Zenke</u> , Darmstadt, DE	
16:45 - 17:05	25IN - DNA and immunotherapy: Synergies of combinations <u>R. Kennedy</u> , Craigavon, GB	
17:05 - 17:15		

07.03.2018

09:00 - 10:30	Cell cycle (CDK4/6) Moderation: G. Shapiro, Boston, US	Room Scene AB
09:00 - 09:20	26IN - Biological outcomes of CDK4/6 inhibition: Induction of senescence <u>A. Koff</u> ¹ , M. Klein ² , M. Dickson ² , C. Antonescu ² , L. Qin ² , S. Dooley ³ , G. Schwartz ¹ , A. Crago ² , S. Singer ² , W. Tap ² ; ¹ New York, US, ² New York, NY/US, ³ Philadelphia, PA/US	
09:20 - 09:40	27IN - The function of cyclin D-CDK4/6 kinases in cancer cell metabolism and anti-tumor immune surveillance <u>P. Sicinski</u> , Boston, US	
09:40 - 10:00	28IN - Emerging mechanisms of CDK4/6 inhibitor acquired resistance <u>V. Serra</u> , Barcelona, ES	
10:00 - 10:20	29IN - Novel utilities of CDK4/6 inhibitors in Rb-negative cells and in combination with immune checkpoint blockade <u>P. Roberts</u> ¹ , A. Lai ² , J. Sorrentino ² , R. Malik ² ; ¹ Research Triangle Park, US, ² Research Triangle Park, NC/US	
10:20 - 10:30	Q&A / Panel Discussion	
10:50 - 12:30	PI3 kinase Moderation: P. Lorusso ¹ , M. Scaltriti ² , U. Banerji ³ ; ¹ Detroit, MI/US, ² New York, NY/US, ³ Sutton, Surrey/GB	Room Scene AB
10:50 - 11:15	30IN - Why is PI3K so hard? <u>M. Scaltriti</u> , New York, NY/US	
11:15 - 11:35	31IN - AKT inhibitors and other new kids on the block <u>L. Siu</u> , Toronto, Ontario/CA	
11:35 - 11:55	32IN - Can adding PI3K inhibitors to the treatment cocktail alter outcome? <u>P. Lorusso</u> , Detroit, MI/US	
11:55 - 12:15	33IN - Other uses of PI3K inhibitors <u>B. Vanhaesebroeck</u> , London, GB	
12:15 - 12:30	Q&A	

13:20 - 14:50	Exploiting immune response diversity Moderation: G. Giaccone, Washington Dc, MD/US	Room Scene AB
13:20 - 13:40	34IN - Impact of microbiome on the efficacy of ICI <u>G. Trinchieri</u> , Bethesda, US	
13:40 - 14:00	35IN - Overview of Intratumoral immunotherapy: therapeutic strategy and the many ongoing trials <u>A. Marabelle</u> , Villejuif, FR	
14:00 - 14:20	36IN - Optimal combination immunotherapy is disease context dependent <u>L. Fong</u> , San Francisco, CA/US	
14:20 - 14:40	37IN - Hyper progressive disease under immunotherapy <u>F. De Braud</u> , M. Di Nicola, S. Damian, S. Cresta, M. Duca, A. Indini, M. Di Bartolomeo, G. Galli, E. Farè, E. Verzoni; Milan, IT	
14:40 - 14:50	Q&A	
15:10 - 16:40	ADC payloads Moderation: G. Giaccone ¹ , A. Tolcher ² ; ¹ Washington Dc, MD/US, ² San Antonio, TX/US	Room Scene AB
15:10 - 15:30	46O - Introduction and presentation of A Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate <u>A. Tolcher</u> ¹ , K. Papadopoulos ¹ , Y. Cole ² , K. Rivas ¹ , S. Chandana ² , S. Sinclair ³ , D. Wood ⁴ , P. Nadler ³ , N. Lakhani ² ; ¹ San Antonio, TX/US, ² Grand Rapids, MI/US, ³ Austin, US, ⁴ Austin, TX/US	
15:30 - 15:50	38IN - Kinesin spindle protein inhibitors as novel payload class for ADCs <u>A. Sommer</u> , Berlin, Berlin/DE	
15:50 - 16:10	39IN - Next generation of radio immunotherapy (RIT) <u>I. Molnar</u> ¹ , E. Burak ² , J. Forbes ² , R. Simms ² , J. Valliant ² ; ¹ Cambridge, US, ² Hamilton, CA	
16:10 - 16:30	40IN - A novel drug conjugate platform: Redefining the therapeutic window for ADCs <u>J. Babcook</u> ¹ , R. Davies ² , S. Barnscher ³ , J. Rich ³ , K. Yin ³ , V. Fung ³ , G. Winters ³ , G. Garnett ³ , P. Kaminker ² , K. Hamblett ² ; ¹ Vancouver, CA, ² Seattle, WA/US, ³ Vancouver, BC/CA	
16:30 - 16:40	Q&A	



16:40 - 16:55 Take home messages and close Room Scene AB

16:40 - 16:55 Take home messages and close
G. Giaccone, Washington, DC/US